12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
In late 2019, Pennsylvania defected from the traditional use of the fluctuating workweek method used...
Read More >
Economic volatility, political unrest and fierce competition are all seen as major challenges to the...
Read More >
On September 18, 2019, Governor Gavin Newsom signed into law Assembly Bill 5, which clarifies when w...
Read More >
A study from T. Rowe Price about 401(k) plan participants had some results that should really not sh...
Read More >
The tender process has long been a staple of the construction industry. Variations of that process, ...
Read More >
After more than two years without one, three ERISA cases will come before the US Supreme Court in 20...
Read More >